1. Th17 and effector CD8 T cells relate to disease progression in amyotrophic lateral sclerosis: a case control study.
- Author
-
Itou T, Fujita K, Okuzono Y, Warude D, Miyakawa S, Mihara Y, Matsui N, Morino H, Kikukawa Y, and Izumi Y
- Subjects
- Humans, Female, Middle Aged, Male, Case-Control Studies, Aged, Adult, Amyotrophic Lateral Sclerosis immunology, Amyotrophic Lateral Sclerosis pathology, Disease Progression, CD8-Positive T-Lymphocytes immunology, Th17 Cells immunology, Th17 Cells metabolism
- Abstract
The immune system has garnered attention due to its association with disease progression in amyotrophic lateral sclerosis (ALS). However, the role of peripheral immune cells in this context remains controversial. Here, we conducted single-cell RNA-sequencing of peripheral blood mononuclear cells to comprehensively profile immune cells concerning the rate of disease progression in patients with ALS. Our analysis revealed increased frequencies of T helper 17 cells (Th17) relative to regulatory T cells, effector CD8 T cells relative to naïve CD8 T cells, and CD16
high CD56low mature natural killer cells relative to CD16low CD56high naïve natural killer cells in patients with rapidly progressive ALS. Additionally, we employed serum proteomics through a proximity extension assay combined with next-generation sequencing to identify inflammation-related proteins associated with rapid disease progression. Among these proteins, interleukin-17 A correlated with the frequency of Th17, while killer cell lectin-like receptor D1 (CD94) correlated with the frequency of effector CD8 T cells. These findings further support the active roles played by these specific immune cell types in the progression of ALS., Competing Interests: Declarations. Ethics approval and consent to participate: All study protocols were approved by the Ethics Committee of Tokushima University Hospital under protocol #3682. All clinical information was collected after patients provided written informed consent. The investigations were conducted following the principles of the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: TI, YO, DW, SM, and YK are employees of Takeda Pharmaceutical Company Limited., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF